Patent application number | Description | Published |
20090156417 | Library From Toxin Mutants, And Methods Of Using Same - This application relates to libraries of ABx toxin mutants, in which a peptide insert is introduced into the protease-sensitive loop of the A-chain sequence to alter the type of cells to which toxic species are delivered. Said libraries are used in the development of therapeutics targeted against specific cell types. | 06-18-2009 |
20090286854 | APTAMERS DIRECTED TO MUCI - Aptamers against the glycosylated form of MUC1 are described, along with their use in treatment and diagnosis of conditions associated with elevated production of MUC1. | 11-19-2009 |
20100297734 | Fusion Tag Comprising an Affinity Tag and an EF-Hand Motif Containing Polypeptide and Methods of Use Thereof - The application discloses a fusion tag comprising an affinity tag and a polypeptide comprising one or more EF hand motif(s). Preferably, said fusion tag comprises a polyhistidine tag, one or more EF hand motif(s) of calmodulin and a thrombin cleavage site. Methods of using said fusion tag to purify a polypeptide of interest are also disclosed. | 11-25-2010 |
20130071417 | N-DOMAIN OF CARCINOEMBRYONIC ANTIGEN AND COMPOSITIONS, METHODS AND USES THEREOF - The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer. | 03-21-2013 |
20130196928 | LIBRARY FROM TOXIN MUTANTS AND METHODS OF USING SAME - This application relates to ABx toxin mutants and libraries of said mutant proteins, in which a peptide insert is introduced into the protease-sensitive loop of the A-chain sequence to alter the type of cells to which toxic species are delivered. Said libraries are used in the development of therapeutics targeted against specific cell types. | 08-01-2013 |
20150044218 | N-DOMAIN OF CARCINOEMBRYONIC ANTIGEN AND COMPOSITIONS, METHODS AND USES THEREOF - The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer. | 02-12-2015 |